Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (ADPT)
NASDAQ:ADPT
ADPT Analyst Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ADPT Stock 12 Month Forecast
Average Price Target
$20.17
▲(36.75% Upside)
| Highest Price Target$22.00 | Average Price Target$20.17 | Lowest Price Target$18.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
―
Buy
―
Reiterated
12/05/25
Buy Rating for Adaptive Biotechnologies: Strong Market Position and Strategic Growth InitiativesWe see Adaptive as the clear market leader with a lengthy head start versus competition. Adaptive’s clonoSEQ test can be used for MRD testing in patients with different blood-cancers like multiple myeloma (MM), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), DLBCL, and mantle cell lymphoma (MCL). Beyond more indications, it is also expanding its moat: increasing reimbursement, becoming more integrated into EMRs, expanding its datasets to support use (including over 90 abstracts at ASH this year), and becoming a leading partner for pharma with clonoSEQ being used as a primary or secondary endpoint in roughly 90 clinical trials. So, a meaningful head start certainly exists and should prove durable, in our view.Still, we understand why shares are down on this news.
Piper Sandler
$20
Buy
35.59%
Upside
Reiterated
12/04/25
Morgan Stanley
$16→$21
Hold
42.37%
Upside
Reiterated
12/01/25
TD Cowen
$15→$22
Buy
49.15%
Upside
Reiterated
11/06/25
Strong Q3 Performance and Market Position Drive Buy Rating for Adaptive BiotechnologiesWe continue to see a mult-year growth & margin story for this heme MRD leader. High-GM MRD ADPT's stock up 193% YTD, investors were optimistic for another strong result in 3Q, and we believe ADPT delivered. MRD sales grew 52% and were 15% ahead of expectations, with clinical MRD sales growing at 83%. In clinical, both volumes (+38% Y/Y; ahead of our 33%) and price (~30% Y/Y; ahead of our 19%) both were drivers. Sequencing Gross margins were ahead, and OpEx modestly below, leading EBITDA ex-Genentech non-cash items to ($6M) vs. our prior ($8.2M), with continued MRD leverage a highlight (2Q 4% to 3Q 12% with a $6.5M milestone). The full year revenue guide was raised by $10M, in line with the MRD upside in 3Q, and OpEx spending lowered, burn reduced.
Craig-Hallum
$18
Buy
22.03%
Upside
Assigned
11/06/25
Guggenheim
$20
Buy
35.59%
Upside
Initiated
09/30/25
BTIG
$14
Buy
-5.08%
Downside
Reiterated
08/19/25
Scotiabank
$12
Buy
-18.64%
Downside
Reiterated
05/05/25
Goldman Sachs
$8→$9
Buy
-38.98%
Downside
Upgraded
03/21/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
―
Buy
―
Reiterated
12/05/25
Buy Rating for Adaptive Biotechnologies: Strong Market Position and Strategic Growth InitiativesWe see Adaptive as the clear market leader with a lengthy head start versus competition. Adaptive’s clonoSEQ test can be used for MRD testing in patients with different blood-cancers like multiple myeloma (MM), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), DLBCL, and mantle cell lymphoma (MCL). Beyond more indications, it is also expanding its moat: increasing reimbursement, becoming more integrated into EMRs, expanding its datasets to support use (including over 90 abstracts at ASH this year), and becoming a leading partner for pharma with clonoSEQ being used as a primary or secondary endpoint in roughly 90 clinical trials. So, a meaningful head start certainly exists and should prove durable, in our view.Still, we understand why shares are down on this news.
Piper Sandler
$20
Buy
35.59%
Upside
Reiterated
12/04/25
Morgan Stanley
$16→$21
Hold
42.37%
Upside
Reiterated
12/01/25
TD Cowen
$15→$22
Buy
49.15%
Upside
Reiterated
11/06/25
Strong Q3 Performance and Market Position Drive Buy Rating for Adaptive BiotechnologiesWe continue to see a mult-year growth & margin story for this heme MRD leader. High-GM MRD ADPT's stock up 193% YTD, investors were optimistic for another strong result in 3Q, and we believe ADPT delivered. MRD sales grew 52% and were 15% ahead of expectations, with clinical MRD sales growing at 83%. In clinical, both volumes (+38% Y/Y; ahead of our 33%) and price (~30% Y/Y; ahead of our 19%) both were drivers. Sequencing Gross margins were ahead, and OpEx modestly below, leading EBITDA ex-Genentech non-cash items to ($6M) vs. our prior ($8.2M), with continued MRD leverage a highlight (2Q 4% to 3Q 12% with a $6.5M milestone). The full year revenue guide was raised by $10M, in line with the MRD upside in 3Q, and OpEx spending lowered, burn reduced.
Craig-Hallum
$18
Buy
22.03%
Upside
Assigned
11/06/25
Guggenheim
$20
Buy
35.59%
Upside
Initiated
09/30/25
BTIG
$14
Buy
-5.08%
Downside
Reiterated
08/19/25
Scotiabank
$12
Buy
-18.64%
Downside
Reiterated
05/05/25
Goldman Sachs
$8→$9
Buy
-38.98%
Downside
Upgraded
03/21/25
Best Analysts Covering Adaptive Biotechnologies
1 Month
xxx
Success Rate
10/21 ratings generated profit
Average Return
-2.31%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.62% of your transactions generating a profit, with an average return of -2.31% per trade.
3 Months
xxx
Success Rate
8/11 ratings generated profit
Average Return
+9.08%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +9.08% per trade.
1 Year
Success Rate
9/12 ratings generated profit
Average Return
+68.26%
reiterated a buy rating last month
Copying Daniel Brennan's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +68.26% per trade.
2 Years
xxx
Success Rate
11/11 ratings generated profit
Average Return
+183.00%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +183.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ADPT Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
0
0
0
0
0
Buy
13
12
13
9
10
Hold
12
10
7
8
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
22
20
17
18
Each month's total comprises the sum of three months' worth of ratings.
ADPT Financial Forecast
ADPT Stock Forecast FAQ
What is ADPT’s average 12-month price target, according to analysts?
Based on analyst ratings, Adaptive Biotechnologies Corp’s 12-month average price target is 20.17.
What is ADPT’s upside potential, based on the analysts’ average price target?
Adaptive Biotechnologies Corp has 36.75% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ADPT a Buy, Sell or Hold?
Adaptive Biotechnologies Corp has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
What is Adaptive Biotechnologies Corp’s price target?
The average price target for Adaptive Biotechnologies Corp is 20.17. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.00 ,the lowest forecast is $18.00. The average price target represents 36.75% Increase from the current price of $14.75.
The highest analyst price target is $22.00 ,the lowest forecast is $18.00. The average price target represents 36.75% Increase from the current price of $14.75.
What do analysts say about Adaptive Biotechnologies Corp?
Adaptive Biotechnologies Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of ADPT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.